Human eosinophils constitutively express a functional interleukin-4 receptor: interleukin-4 -induced priming of chemotactic responses and induction of PI-3 kinase activity.
Similar to interleukin-3 (IL-3), IL-5, and granulocyte macrophage colony-stimulating factor (GM-CSF), IL-4 can be secreted by several cell types involved in allergic inflammatory reactions, and therefore can affect eosinophil function similarly. In this study, we investigated the presence of an IL-4 receptor (IL-4R) on human eosinophils. When two different monoclonal antibodies (mAbs) against the IL-4R alpha-chain (IL-4Ralpha) were used, fluorescent-activated cell sorter analysis revealed the presence of an IL-4Ralpha on both eosinophils of normal donors and atopic dermatitis patients. In addition, the expression of the IL-2R gamma-chain, a functional component of the IL-4R in some cell types, was demonstrated. The IL-4Ralpha appeared to be expressed constitutively, and stimulation with cytokines IL-2, IL-3, IL-5, GM-CSF, and interferon-gamma did not further increase IL-4Ralpha expression. Evidence for an IL-4Ralpha was further substantiated by mRNA analysis. Both Northern blot analysis and reverse transcriptase/polymerase chain reaction revealed the presence of mRNA for the IL-4Ralpha in eosinophils from normal individuals and AD patients. Furthermore, we demonstrated that both IL-4 and IL-13 were capable of inducing PI-3 kinase activity in human eosinophils. Because this activation could be inhibited by an IL-4Ralpha mAb, we conclude that both cytokines can activate human eosinophils through binding to a receptor complex comprising the IL-4Ralpha and-yet to be identified-associated proteins. In addition, the involvement of IL-4 in functional responses was studied. IL-4 appeared to "prime" eosinophils to respond chemotactically toward regulated on activation, normal T cells expressed and secreted, but did not affect platelet-activating factor-induced chemotaxis. Taken together, these data show the presence of a functional IL-4R on human eosinophils.
Dubois
G R
GR
Departments of Dermatology/Allergology and Pulmonary Diseases, University Hospital Utrecht, The Netherlands.
Schweizer
R C
RC
Versluis
C
C
Bruijnzeel-Koomen
C A
CA
Bruijnzeel
P L
PL
D000911:Antibodies, Monoclonal; D015152:Blotting, Northern; D018946:Chemokine CCL5 / Q000378:metabolism; D002633:Chemotaxis / Q000187:drug effects* / Q000276:immunology; D003876:Dermatitis, Atopic / Q000276:immunology; D004789:Enzyme Activation / Q000187:drug effects / Q000276:immunology; D004804:Eosinophils / Q000737:chemistry* / Q000187:drug effects / Q000201:enzymology; D005434:Flow Cytometry; D015870:Gene Expression / Q000276:immunology; D006801:Humans; D018793:Interleukin-13 / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology*; D016393:Lymphoma, B-Cell; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis; D019948:Receptors, Interleukin-4 / Q000032:analysis / Q000235:genetics* / Q000276:immunology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000276:immunology
D000911:Antibodies, Monoclonal; D018946:Chemokine CCL5; D018793:Interleukin-13; D012333:RNA, Messenger; D019948:Receptors, Interleukin-4; D015847:Interleukin-4; D019869:Phosphatidylinositol 3-Kinases